On the other hand, RAS/MAPK pathway is activated in 50–100% of HCC patients and shows a correlation to poor prognosis [26], and RAS-BRAF pathway was reported to affect HCC [25, 27, 28]. This evidence concerns the gene BRAF and hepatocellular carcinoma.